We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A COMparison Between PAClitaxel-coated Balloon and pacliTaxel-eluting Stent in the Treatment of In-Stent Restenosis (COMPACT-ISR) (COMPACT-ISR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01204320
Recruitment Status : Terminated
First Posted : September 17, 2010
Last Update Posted : September 17, 2010
Information provided by:
Ospedale San Donato

Brief Summary:
This is a multicentric randomized comparison between paclitaxel-coated balloon angioplasty or paclitaxel-eluting stent implantation in patients with stable or unstable angina with the evaluation of restenosis by Quantitative Coronary Analysis.

Condition or disease Intervention/treatment Phase
Stable Angina Unstable Angina Procedure: Paclitaxel-coated Balloon Device: Paclitaxel-eluting Stent Phase 4

Detailed Description:
The purpose of this study is to determine the late luminal loss by Quantitative Coronary Analysis at 6 month-follow up after paclitaxel-coated balloon angioplasty or paclitaxel-eluting stent implantation in the treatment of in-stent restenosis.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 154 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Study Start Date : January 2008
Estimated Primary Completion Date : January 2010

Resource links provided by the National Library of Medicine

Drug Information available for: Paclitaxel
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Paclitaxel-coated Balloon
Paclitaxel-coated Balloon Angioplasty
Procedure: Paclitaxel-coated Balloon
Other Name: Orbus
Active Comparator: Paclitaxel-eluting Stent
Paclitaxel-eluting Stent Implantation
Device: Paclitaxel-eluting Stent
Other Name: Taxus

Primary Outcome Measures :
  1. Late Luminal Loss defined as the difference between the minimal luminal diameter after stenting and at follow-up by Quantitative Coronary Analysis [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Binary restenosis defined as >50% diameter stenosis by QCA [ Time Frame: 6 months ]
  2. Major Adverse Cardiac Events [ Time Frame: 6, 12 months ]
  3. Target Lesion Revascularization [ Time Frame: 6, 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • informed consent
  • >18y
  • Stable Angina or Unstable Angina
  • Single restenotic lesion in a previously stented coronary artery

Exclusion Criteria:

  • Acute Myocardial Infarction within 72h
  • Serum Creatinine>2.0 mg/dL
  • Contraindications to ASA, Heparin, Clopidogrel, Ticlopidine, Abciximab, Tirofiban, Paclitaxel
  • Contraindications to contrast media
  • Life expectancy < 2y
  • Target Lesion length > 30mm
  • Target Lesion diameter <= 2.5 mm
  • Target stenosis < 70%
  • Massive Calcifications in the target segment
  • Evidence of intra-coronary thrombus

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01204320

San Donato Hospital
Arezzo, AR, Italy, 52100
Sponsors and Collaborators
Ospedale San Donato
Study Chair: Leonardo Bolognese, MD Cardiovascular Department - San Donato Hospital

Responsible Party: Cardiovascular Department USL 8(Leonardo Bolognese MD), Ospedale SanDonato
ClinicalTrials.gov Identifier: NCT01204320     History of Changes
Other Study ID Numbers: Arezzo003
First Posted: September 17, 2010    Key Record Dates
Last Update Posted: September 17, 2010
Last Verified: October 2009

Keywords provided by Ospedale San Donato:

Additional relevant MeSH terms:
Angina Pectoris
Angina, Stable
Angina, Unstable
Chest Pain
Neurologic Manifestations
Nervous System Diseases
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Signs and Symptoms
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action